

Journal Pre-proof

The spectrum of COVID-19-associated dermatologic manifestations: an international registry of 716 patients from 31 countries

Esther E. Freeman, MD PhD, Devon E. McMahon, BA, Jules B. Lipoff, MD, Misha Rosenbach, MD, Carrie Kovarik, MD, Seemal R. Desai, MD, Joanna Harp, MD, Junko Takeshita, MD PhD MSCE, Lars E. French, MD, Henry W. Lim, MD, Bruce H. Thiers, MD, George J. Hruza, MD MBA, Lindy P. Fox, MD



PII: S0190-9622(20)32126-5

DOI: <https://doi.org/10.1016/j.jaad.2020.06.1016>

Reference: YMJD 14915

To appear in: *Journal of the American Academy of Dermatology*

Received Date: 25 May 2020

Revised Date: 20 June 2020

Accepted Date: 23 June 2020

Please cite this article as: Freeman EE, McMahon DE, Lipoff JB, Rosenbach M, Kovarik C, Desai SR, Harp J, Takeshita J, French LE, Lim HW, Thiers BH, Hruza GJ, Fox LP, The spectrum of COVID-19-associated dermatologic manifestations: an international registry of 716 patients from 31 countries, *Journal of the American Academy of Dermatology* (2020), doi: <https://doi.org/10.1016/j.jaad.2020.06.1016>.

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2020 Published by Elsevier on behalf of the American Academy of Dermatology, Inc.

Capsule Summary

- In this international registry, the most common dermatologic morphologies in 171 COVID-19 lab-confirmed cases included morbilliform (22%), pernio-like (18%), urticarial (16%), macular erythema (13%), vesicular (11%), papulosquamous (9.9%), and retiform purpura (6.4%).
- Pernio-like lesions were noted in mild disease while retiform purpura was seen exclusively in critically ill patients.

**The spectrum of COVID-19-associated dermatologic manifestations:
an international registry of 716 patients from 31 countries**

Authors: Esther E. Freeman MD PhD,^{1,2} Devon E. McMahon BA,¹ Jules B. Lipoff MD,³ Misha Rosenbach MD,³ Carrie Kovarik MD,³ Seemal R. Desai MD,⁴ Joanna Harp MD,⁵ Junko Takeshita MD PhD MSCE,³ Lars E. French MD,^{6,7} Henry W. Lim MD,⁸ Bruce H. Thiers MD,⁹ George J. Hruza MD MBA,¹⁰ Lindy P. Fox MD¹¹

¹Department of Dermatology, Massachusetts General Hospital, Harvard Medical School, Boston, MA; ²Medical Practice Evaluation Center, Mongan Institute, Massachusetts General Hospital, Boston, MA; ³Department of Dermatology, University of Pennsylvania, Philadelphia, PA; Department of Dermatology; ⁴The University of Texas Southwestern Medical Center, Dallas, Texas, Innovative Dermatology, Plano, Texas; ⁵Department of Dermatology, Weill Cornell Medicine, New York, NY; ⁶Department of Dermatology, University Hospital, Munich University of Ludwig Maximilian, Munich, Germany; Department of Dermatology, ⁷Dr. Phillip Frost Department of Dermatology & Cutaneous Surgery, University of Miami, Miller School of Medicine, ⁸Department of Dermatology, Henry Ford Health System, Detroit, MI, USA; ⁹Department of Dermatology and Dermatologic Surgery, Medical University of SC, Charleston, SC; ¹⁰Department of Dermatology, St. Louis University, St. Louis, MO; ¹¹Department of Dermatology, University of California San Francisco, San Francisco, CA

Corresponding Author:

Esther Freeman, MD, PhD
Massachusetts General Hospital
55 Fruit St, Boston, MA 02114
Email: efreeman@mgh.harvard.edu

Category: Original Article

Capsule word count: 49

Abstract word count: 150

Manuscript word Count: 2500

Reference Count: 31

Tables/Figures: 4 Tables; 1 Figure; 2 supplemental tables; 1 supplemental figure (supplemental material available at <https://data.mendeley.com/datasets/gh945hpwy3/1>)

Keywords: COVID-19; SARS-CoV-2; dermatology; public health; registry; pernio; COVID toes; morbilliform; urticarial; vesicular; macular erythema; retiform purpura; global health

Funding: None

Disclosures: Drs. Freeman, Lipoff, Rosenbach, Kovarik, Desai, Takeshita, Hruza Thiers and Fox are part of the American Academy of Dermatology (AAD) COVID-19 Ad Hoc Task Force. Dr. French is president and Dr. Lim is board member of the International League of Dermatological Societies (ILDS). Dr. Hruza is immediate past president of the AAD. Dr. Thiers is the President of the AAD.

Ethics: The registry was reviewed by the Partners Healthcare (MGH) Institutional Review Board (IRB) and was determined to not meet the definition of Human Subjects Research.

Capsule Summary

- In this international registry, the most common dermatologic morphologies in 171 COVID-19 lab-confirmed cases included morbilliform (22%), pernio-like (18%), urticarial (16%), macular erythema (13%), vesicular (11%), papulosquamous (9.9%), and retiform purpura (6.4%).
- Pernio-like lesions were noted in mild disease while retiform purpura was seen exclusively in critically ill patients.

Abstract

Background: Coronavirus disease 2019 (COVID-19) has associated cutaneous manifestations.

Objective: To characterize the diversity of cutaneous manifestations of COVID-19, and facilitate understanding of underlying pathophysiology.

Methods: Case series from an international registry from the American Academy of Dermatology and International League of Dermatological Societies.

Results: The registry collected 716 cases of new-onset dermatologic symptoms in patients with confirmed/suspected COVID-19. Of the 171 patients in the registry with laboratory-confirmed COVID-19, the most common morphologies were morbilliform (22%), pernio-like (18%), urticarial (16%), macular erythema (13%), vesicular (11%), papulosquamous (9.9%), and retiform purpura (6.4%). Pernio-like lesions were common in patients with mild disease, while retiform purpura presented exclusively in ill, hospitalized patients.

Limitations: We cannot estimate incidence or prevalence. Confirmation bias is possible.

Conclusion: This study highlights the array of cutaneous manifestations associated with COVID-19. Many morphologies were non-specific, while others may provide insight into potential immune or inflammatory pathways in COVID-19 pathophysiology.

Background

Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has associated cutaneous manifestations.¹ Case series have documented pernio-like lesions,²⁻⁷ erythematous macules or papules,^{5, 6, 8} urticarial,^{8, 9} morbilliform,⁹ varicelliform,^{5, 6, 8-10} papulosquamous,¹¹ petechial eruptions,^{9, 12} livedo reticularis-like rashes,^{5, 9} purpuric lesions,⁵ acro-ischemic lesions¹³ and retiform purpura.¹⁴ The timing of eruptions in the disease course and potential associations between morphological subtypes with different COVID-19-associated syndromes and/or outcomes remain unclear.

Dermatologic manifestations of infectious diseases are important for identifying and treating viral illnesses including HIV, dengue, and chikungunya. Expert guidance in recognizing these signs represents an opportunity to improve diagnosis and management. Identification and characterization of COVID-19 skin lesions, like the well-described association with anosmia, may prompt suspicion for SARS-CoV-2 infection.¹⁵ Thus, dermatologists at Harvard Medical School and Massachusetts General Hospital created the COVID-19 Dermatology Registry, and in collaboration with the American Academy of Dermatology and International League of Dermatologic Societies, invited healthcare workers globally to submit data for possible cutaneous manifestations of confirmed or suspected COVID-19.¹⁶

For this study, we aimed to: (1) characterize internationally representative cutaneous manifestations of confirmed/suspected COVID-19 and (2) identify cutaneous manifestations that may provide insight into pathophysiology and disease course of COVID-19.

Methods

In collaboration with the AAD and ILDS, we established an international registry to collect cases of COVID-19 cutaneous manifestations (www.aad.org/covidregistry); the registry is open to medical professionals only, from any specialty.⁷ No protected health information was collected and all data was de-identified. The registry collected COVID-19 diagnosis type (suspected vs. laboratory-confirmed), demographics, comorbidities, dermatologic condition details, timing of symptoms, skin biopsy results, COVID-19 symptoms and outcomes, including hospitalization, oxygen and ventilator requirements, and deaths. Providers were prompted by email for case updates.

Suspected or laboratory-confirmed COVID-19 cases with new-onset dermatologic findings were eligible for inclusion in initial analysis. Patients whose eruptions were favored as drug-induced by submitting healthcare providers were analyzed separately. Additional analysis was performed on the laboratory-confirmed COVID-19

patient subgroup. For patients with pernio-like lesions, we excluded those with prior pernio history. Data was analyzed using Stata (Version 16). The Partners Healthcare Institutional Review Board approved this study, which did not meet the definition of Human Subjects Research.

Results

From April 8-May 17, 2020, 716 cases of new onset dermatologic manifestations in the setting of confirmed/suspected COVID-19 were entered into the registry by dermatologists (54%), other physicians (32%), mid-level practitioners (7.3%), nurses (2.8%), and other medical professionals (3.4%). Cases were reported from 31 countries, most (89%) from the United States. Seven cases designated by providers as medication-induced were analyzed separately and excluded from sub-group analysis of laboratory confirmed cases (Supplemental Table 1) and 27 cases with prior pernio history were excluded. 171 cases (25%) were laboratory-confirmed: 135 by PCR, 19 by antibody, and 17 by unspecified testing (positive COVID-19 laboratory assay, but the specific test performed was unreported or unknown). The median age of patients with laboratory-confirmed COVID-19 was 44 years (IQR 28-61), and 54% were female (Table 1).

In the 171 laboratory-confirmed COVID-19 patients, the most common morphologies were morbilliform (22%), pernio-like (18%), urticarial (16%), macular erythema (13%), vesicular (11%), papulosquamous (9.9%), and retiform purpura (6.4%) (for clinical photos, see Supplemental Figure 1). A sub-group analysis of patients submitted by dermatologists showed similar distribution (Supplemental Table 2). A minority of patients presented with multiple morphologies, including 4 cases of morbilliform plus urticarial rash, and 2 cases of morbilliform plus pernio. Six reports involved mucous membranes (4 of oral mucosa and 2 of conjunctivae). Of 17 reports of edema, most (71%) were associated with another cutaneous finding.

Skin symptoms and affected body sites varied by morphology (Table 2). For example, morbilliform morphologies were often pruritic and involved the trunk, whereas pernio morphologies often caused pain/burning and involved feet/hands. The face was involved in 21% of morbilliform rashes. Retiform purpura were on the extremities and buttocks. The full course of laboratory-confirmed rashes lasted median seven days (IQR 3-10). Pernio, however, had a longer course with median 14 days (IQR 8-24). Full duration could only be determined for resolved lesions. Most patients (72%) had ongoing lesions; therefore, these values may underestimate duration.

Lesions generally occurred after (64%) or concurrent (15%) with other COVID-19 symptoms. In particular, skin lesions occurred after COVID-19 symptoms for morbilliform (76%), pernio-like (48%), urticarial (67%),

macular erythema (57%), vesicular (72%), papulosquamous (53%) and retiform purpura (91%) morphologies. A minority occurred prior to other COVID-19 symptoms (12%).

Many patients with laboratory-confirmed COVID-19 and dermatologic findings had no clear documented COVID-19 exposure (Table 3). The most common COVID-19 symptoms among laboratory-confirmed cases included fever (61%) and cough (59%) (Table 3). With respect to CDC-defined PCR-test qualifying symptoms, patients with pernio-like skin lesions met fewer CDC testing criteria, meeting three or more criteria in 29%, compared to morbilliform eruptions (55%), urticaria (70%), macular erythema (74%), or vesicular eruptions (61%).¹⁷ An additional 8.8% of patients with laboratory-confirmed COVID-19 were asymptomatic aside from rash. Pernio-like lesions were not associated with other COVID-19 symptoms in 19%.

The most common medical co-morbidities included hypertension (16%), diabetes (12%), and smoking (12%). Most patients did not receive COVID-19-specific treatment (60%). For the 69 patients receiving COVID-19 treatment, 55% received antimalarials and 50% antibiotics including azithromycin (56%), ceftriaxone (37%), vancomycin (37%), piperacillin-tazobactam (29%), and doxycycline (27%). Treatment preceded the COVID-19-associated dermatologic condition in 56%. For morbilliform rashes, 37% received no treatment, 15% received treatment before morbilliform rashes started, and 48% received treatment after morbilliform rash onset.

Hospitalization varied: 16% of patients with pernio-like lesions were hospitalized, compared to 35% for all other COVID-19 dermatologic manifestations. Patients with retiform purpura tended to be sicker; 100% were hospitalized and 82% had Acute Respiratory Distress Syndrome (ARDS) (Table 3) (Figure 1). For the 60 hospitalized patients with laboratory-confirmed COVID-19, 24 (40%) required invasive mechanical ventilation and/or extracorporeal membrane oxygenation (ECMO), and 17 (28%) required supplemental oxygen. The most common complication was ARDS, in 23 (38%). Ten patients died, including those with morbilliform rash and macular erythema (2), urticaria (1), acrocyanosis and pernio-like lesions (1), acrocyanosis (1), livedo-reticularis (1), retiform purpura (2), livedo racemosa (1), retiform purpura and livedo racemosa (1), and pernio-like lesions, acrocyanosis and petechiae (1).

Dermatopathology (Table 4) was available from fourteen laboratory-confirmed cases (fifteen total biopsies). Six cases with clinical retiform purpura and/or livedo racemosa demonstrated thrombotic vasculopathy. One case clinically described as buttock pressure injury also showed thrombotic vasculopathy. Another patient with complicated hospital course also developed buttock pressure injury and retiform purpura, but the biopsy only showed clotting and pressure necrosis. One palpable purpura case with ulceration demonstrated leukocytoclastic vasculitis. Two patients with papulosquamous morphologies demonstrated spongiosis and dermal inflammation.

One case with pernio-like lesions had vacuolar interface dermatitis, subepidermal edema, and superficial and deep lymphocytic inflammation. One case with an acrally distributed petechial, macular and urticarial eruption demonstrated diffuse vacuolar interface dermatitis with numerous dyskeratotic keratinocytes, sparse perivascular lymphohistiocytic inflammation, and rare dermal eosinophils.

Discussion

This study highlights the wide variety of cutaneous manifestations of COVID-19 reported concurrently with or after COVID-19 diagnosis. The most common morphologies in laboratory-confirmed cases in our registry include morbilliform, pernio-like, urticarial, macular erythematous, vesicular, papulosquamous, and retiform purpura. Many of these morphologies occur with different viral infections and thus may not provide specific insight into pathophysiology or treatment targets. However, others may suggest potential immune or inflammatory pathways involved in COVID-19 pathogenesis. Further, by documenting this constellation of cutaneous manifestations, we hope to inform providers to more accurately identify signs of COVID-19. Cutaneous COVID-19 manifestations generally presented simultaneous to or after other COVID-19 symptoms. However, 12% occurred before other COVID-19 signs, highlighting their importance in assisting COVID-19 detection.

Similar to previous reports, pernio-like lesions were reported more than other dermatologic manifestations.^{1, 7, 9} The high frequency of these reports may reflect the media attention pernio-like lesions received, especially in April/May 2020, with providers potentially sensitized to enter cases even without laboratory-confirmation.^{18, 19} However, restricted to laboratory-confirmed sub-group analysis, morbilliform and/or macular erythema presentations were more common. Similarly, a Spanish case series reported half of laboratory-confirmed COVID-19 dermatologic manifestations as “maculopapular,” 19% pernio-like, and 19% urticarial.⁶

Thirty-one patients with pernio-like lesion had laboratory-confirmed COVID-19, including 16 who were PCR positive, and therefore possibly infectious. Given public health risks posed by COVID-19, new onset of pernio-like lesions should prompt patient-provider discussions regarding both testing with PCR and/or antibody assays and the role of self-isolation in concordance with local and national guidelines. Reassuringly, pernio-like lesions usually appeared in patients with relatively mild COVID-19 disease courses; these patients had fewer other COVID-19 symptoms and lesser severity (5/31 hospitalized, 2 deaths). How this relates to immune response to the virus and likelihood for complications remains unclear. If not coincidental, perhaps the underlying mechanism that predisposed patients to pernio-like lesions is protective, suggesting pernio may be a marker of a robust, effective host anti-viral response limiting COVID-19 complications.²⁰ While we cannot completely exclude

epiphenomena, as patients may notice foot lesions more and be more likely to seek care, this cluster is unusual. New cases appeared in geographies where winter temperatures remained $>10^{\circ}\text{C}$ and continue even during late spring's warmer weather.

Of patients with other dermatologic manifestations of COVID-19, including morbilliform eruptions, macular erythema, urticaria, and vesicular rashes, 22-45% were hospitalized, with 3 deaths. However, fixed livedo racemosa, retiform purpura, and true acral ischemia appeared in critically ill patients, corroborating others' findings.^{6, 14} Given occurrence on acral surfaces, these morphologies should be distinguished from pernio-like lesions. In acral livedo racemosa, retiform purpura, and acro-ischemia, the histopathologic findings presented here demonstrate non-inflammatory to pauci-inflammatory thrombi without other findings often associated with pernio, such as vacuolar interface changes with associated necrotic keratinocytes, papillary derma edema, and a superficial and deep dermal lymphocytic infiltrate. This suggests that thrombotic disease in critically ill COVID-19 patients may extend to the skin in patients with livedo racemosa/retiform purpura/acro-ischemia, with a morphology distinct from pernio.¹⁴ One study implicated activation of the alternative complement pathway cutaneous thrombosis pathophysiology.¹⁴ Placentas in mothers with mild COVID-19 showed no viral infection but abnormal thrombus formation in the absence of complement activation, suggesting systemic coagulopathy may not involve complement pathway activation in all patients.²¹ Why some patients develop severe coagulopathy while others do not remains under active investigation.

Accurate evaluation and morphologic descriptions of subtle physical exam findings, including consideration of whether lesions are appropriate for skin biopsy, are important in evaluating acral lesions in patients with known/suspected COVID-19. This nuance is especially true in patients with skin of color where the examination of frank erythema and pernio-like lesions may be challenging. In darker skin types (Fitzpatrick IV-VI), more assiduous examination is important as erythema may clinically manifest as subtler dark purple/brown hyperpigmentation.

Beyond assisting clinical examination, we sought to identify dermatologic manifestations of COVID-19 to improve understanding of SARS-CoV-2 pathophysiology. Previously, Suchonwanit²² proposed that cutaneous manifestations in COVID-19 may present in two mechanistic patterns: (1) clinical features similar to viral exanthems, an immune response to viral nucleotides; and (2) cutaneous eruptions secondary to COVID-19 systemic consequences, especially vasculitis and thrombotic vasculopathy. Although this suggested dichotomy is a loose framework, it may prove a good starting point to consider our findings.

For instance, pernio-like lesions may offer an opportunity for deeper understanding of both the pathophysiology of SARS-CoV-2 and pernio as a reaction pattern with multiple etiologies. The underlying cause of pernio-like lesions from the pathology collected suggests a primary inflammatory process. Pernio-like lesions are generally non-ischemic and, thus far, do not suggest systemic intravascular thromboses, unlike retiform purpura and acral ischemia. Interferonopathies, genetic conditions with overproduction of type I interferons, may present with pernio-like lesions, suggesting a robust interferon response in the pathogenesis of perniosis.²³ Type I interferon is critical for anti-viral immunity, and thus its heightened production in young, healthy people exposed to SARS-CoV-2 is expected and would lead to successful viral control but also, hypothetically, could trigger pernio.²⁴ Indeed, a low/delayed interferon response might allow for uncontrolled viral replication and a subsequent cytokine storm leading to severe illness and low incidence of pernio.²⁴ SARS-CoV-2-infected Chinese patients with interferon-induced transmembrane protein-3 gene polymorphism may develop worsening disease in an age-dependent fashion, suggesting an interferon-driven anti-viral response could be necessary for early viral control.²⁵

Our study is limited by the constraints of a case series, which cannot accurately estimate prevalence nor incidence of these findings. The incidence of COVID-19 dermatologic manifestation remains unclear, with studies reporting 0.2% to 20%.^{8, 26, 27} There also remains the possibility of bias due to attribution error, given reliance on providers' judgment entering data, if findings were virus-related or from a medication or other causes. Although providers were prompted for case updates, most reports represent a single snapshot, preventing full observation of dermatologic manifestations, disease complications, and follow-up testing. Limited testing of COVID-19 remains a persistent issue. Only 25% of our patients had laboratory-confirmed disease. It is difficult to parse the effects of poor test access and false negative tests on our data. Furthermore, this registry represents a small sample of global dermatologic manifestations; American dermatology networks received the most promotion, as our results reflect. Additionally, providers may have been more likely to enter more severe cases.

The lack of a clear definition for COVID-19-associated skin findings may restrict extrapolation from these data, e.g. the non-specific term "Covid toes," which may incorporate a variety of acral lesions. Only half of medical professionals entering cases were dermatologists, making morphologic misclassification possible; without photographs to confirm, we cannot ensure consistent description. As more data emerge, we should examine specific subsets (e.g. such as angulated distal purpura, erythema multiforme-like lesions, and true pernio-like lesions) that may have distinct clinical morphologies, histologic patterns, and pathophysiology. Nevertheless, we believe that better recognition of these manifestations, whether from the disease itself or from medications for COVID-19, will provide insight into disease characterization and management.²⁸

Our cases lacked diversity in representation, with only 34 Hispanic/Latino and 13 Black/African-American patients. This poor racial/ethnic diversity in the classification of COVID-19 dermatologic manifestations is problematic, especially given that photos of these lesions in darker skin types may help patients and providers identify early signs of COVID-19.²⁹ Disparities in number of COVID-19 hospitalizations and outcomes demonstrate disproportionate impact on these populations.³⁰ Lack of race and ethnicity data reporting in state health department registries of COVID-19 cases has complicated this issue.³¹ Early recognition, diagnosis, and management of cutaneous manifestations of COVID-19 in patients with skin of color provides an additional way in which healthcare providers can help care for underrepresented minority populations, thereby reducing the healthcare disparities seen with COVID-19.

In conclusion, we demonstrate a spectrum of COVID-19-related dermatoses. These cutaneous manifestations may present with other COVID-19 symptoms, and others may represent post-viral inflammatory responses. Our study highlights that pernio-like lesions are associated with milder COVID-19 disease courses while retiform purpura is associated with severe disease in critically ill patients. Further investigation is needed to precisely ascertain timing of findings, the pathophysiology behind different morphologies, and potential antibody response in patients who may only have mild COVID-19 symptoms.³²⁻³⁶ Dermatologic findings should not be overlooked as signs of COVID-19 and should prompt discussions between physicians and patients regarding isolation and possible testing.

Acknowledgements

We would like to acknowledge Drs. Dawn Thompson, James Melia, Kristin Poshkus, Sanah Ali, Laura Braham, Antonia Calvo Cano, Pamela Davis, Javier Gelvez, Samuel Gettler, Hector Iglesias, Neelam Neupane, Nicole Rocca, Sabrina Newman, Frankie Marmolejo, Vesna Petronic-Rosic, Noufal Raboobee, Elizabeth Seiverling, Denise Grace, Andrea Maderal, Adelaida Solomon, John Bartolini, and Emily Wise for providing clinical photographs. We would also like to acknowledge Drs. Rina Allawh, Rebecca Tamez, Jennifer Abrahams, Clara Cokonis, Laura Jerome, Edward Butler, and Tess Peters for providing dermatopathology results. We appreciate all the healthcare providers worldwide who entered cases in this registry.

References:

1. Jia JL, Kamceva M, Rao SA, Linos E. Cutaneous Manifestations of COVID-19: A Preliminary Review. *J Am Acad Dermatol* 2020.
2. Fernandez-Nieto D, Jimenez-Cauhe J, Suarez-Valle A, Moreno-Arrones OM, Saceda-Corralo D, Arana-Raja A et al. Characterization of acute acro-ischemic lesions in non-hospitalized patients: a case series of 132 patients during the COVID-19 outbreak. *J Am Acad Dermatol* 2020.
3. Piccolo V, Neri I, Filippeschi C, Oranges T, Argenziano G, Battarra VC et al. Chilblain-like lesions during COVID-19 epidemic: a preliminary study on 63 patients. *J Eur Acad Dermatol Venereol* 2020.
4. Recalcati S, Barbagallo T, Frasin LA, Prestinari F, Cogliardi A, Provero MC et al. Acral cutaneous lesions in the Time of COVID-19. *J Eur Acad Dermatol Venereol* 2020.
5. Bouaziz JD, Duong T, Jachiet M, Velter C, Lestang P, Cassius C et al. Vascular skin symptoms in COVID-19: a french observational study. *J Eur Acad Dermatol Venereol* 2020.
6. Galvan Casas C, Catala A, Carretero Hernandez G, Rodriguez-Jimenez P, Fernandez Nieto D, Rodriguez-Villa Lario A et al. Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases. *Br J Dermatol* 2020.
7. Freeman EE, McMahon DE, Lipoff JB, Rosenbach M, Kovarik C, Takeshita J et al. Pernio-like skin lesions associated with COVID-19: a case series of 318 patients from 8 countries. *J Am Acad Dermatol* 2020.
8. Recalcati S. Cutaneous manifestations in COVID-19: a first perspective. *J Eur Acad Dermatol Venereol* 2020.
9. de Masson A, Bouaziz JD, Sulimovic L, Cassius C, Jachiet M, Ionescu MA et al. Chilblains are a common cutaneous finding during the COVID-19 pandemic: a retrospective nationwide study from France. *J Am Acad Dermatol* 2020.
10. Marzano AV, Genovese G, Fabbrocini G, Pigatto P, Monfrecola G, Piraccini BM et al. Varicella-like exanthem as a specific COVID-19-associated skin manifestation: multicenter case series of 22 patients. *J Am Acad Dermatol* 2020.
11. Sanchez A, Sohier P, Benghanem S, L'Honneur AS, Rozenberg F, Dupin N et al. Digitate Papulosquamous Eruption Associated With Severe Acute Respiratory Syndrome Coronavirus 2 Infection. *JAMA Dermatol* 2020.
12. Diaz-Guimaraens B, Dominguez-Santas M, Suarez-Valle A, Pindado-Ortega C, Selda-Enriquez G, Bea-Ardebol S et al. Petechial Skin Rash Associated With Severe Acute Respiratory Syndrome Coronavirus 2 Infection. *JAMA Dermatol* 2020.

13. Zhang Y, Cao W, Xiao M, Li YJ, Yang Y, Zhao J et al. [Clinical and coagulation characteristics of 7 patients with critical COVID-2019 pneumonia and acro-ischemia]. *Zhonghua Xue Ye Xue Za Zhi* 2020;41:E006.
14. Magro C, Mulvey JJ, Berlin D, Nuovo G, Salvatore S, Harp J et al. Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: A report of five cases. *Transl Res* 2020.
15. Tong JY, Wong A, Zhu D, Fastenberg JH, Tham T. The Prevalence of Olfactory and Gustatory Dysfunction in COVID-19 Patients: A Systematic Review and Meta-analysis. *Otolaryngol Head Neck Surg* 2020:194599820926473.
16. Freeman EE, McMahon DE, Fitzgerald ME, Fox LP, Rosenbach M, Takeshita J et al. The AAD COVID-19 Registry: Crowdsourcing Dermatology in the Age of COVID-19. *J Am Acad Dermatol* 2020.
17. Evaluating and Testing Persons for Coronavirus Disease 2019 (COVID-19).
18. Rabin R. What Is 'Covid Toe'? Maybe a Strange Sign of Coronavirus Infection. May 1 2020. *The New York Times*. <https://www.nytimes.com/2020/05/01/health/coronavirus-covid-toe.html> (accessed June 18, 2020).
19. Cha A. 'Frostbite' toes and other peculiar rashes may be signs of hidden coronavirus infection, especially in the young. April 29 2020. *The Washington Post*. <https://www.washingtonpost.com/health/2020/04/29/coronavirus-rashes-toes/> (accessed June 18, 2020).
20. Freeman E, McMahon D, Lipoff J, Rosenbach M, Kovarik C, Takeshita J et al. Pernio-like skin lesions associated with COVID-19: a case series of 318 patients from 8 countries. *J Am Acad Dermatol* 2020 (In Press)
21. Zakraoui L, Jeridi T, Chekir T, Cheour I, Bouslama K, Hila A et al. [Clinico-biological profile of systemic scleroderma apropos of 25 cases]. *Tunis Med* 1988;66:821-32.
22. Suchonwanit P, Leerunyakul K, Kositkuljorn C. Cutaneous manifestations in COVID-19: Lessons learned from current evidence. *J Am Acad Dermatol* 2020.
23. Fiehn C. Familial Chilblain Lupus - What Can We Learn from Type I Interferonopathies? *Curr Rheumatol Rep* 2017;19:61.
24. Jamilloux Y, Henry T, Belot A, Viel S, Fauter M, El Jammal T et al. Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions. *Autoimmun Rev* 2020:102567.
25. Zhang Y, Qin L, Zhao Y, Zhang P, Xu B, Li K et al. Interferon-induced transmembrane protein-3 genetic variant rs12252-C is associated with disease severity in COVID-19. *J Infect Dis* 2020.

26. De Giorgi V, Recalcati S, Jia Z, Chong W, Ding R, Deng Y et al. Cutaneous manifestations related to coronavirus disease 2019 (COVID-19): A prospective study from China and Italy. *J Am Acad Dermatol* 2020.
27. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX et al. Clinical Characteristics of Coronavirus Disease 2019 in China. *N Engl J Med* 2020;382:1708-20.
28. Madigan LM, Micheletti RG, Shinkai K. How Dermatologists Can Learn and Contribute at the Leading Edge of the COVID-19 Global Pandemic. *JAMA Dermatol* 2020.
29. Lester JC, Jia JL, Zhang L, Okoye GA, Linos E. Absence of Skin of Colour Images in Publications of COVID-19 Skin Manifestations. *Br J Dermatol* 2020.
30. Dyer O. Covid-19: Black people and other minorities are hardest hit in US. *BMJ* 2020;369:m1483.
31. Laurencin CT, McClinton A. The COVID-19 Pandemic: a Call to Action to Identify and Address Racial and Ethnic Disparities. *J Racial Ethn Health Disparities* 2020.
32. To KK, Tsang OT, Leung WS, Tam AR, Wu TC, Lung DC et al. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study. *Lancet Infect Dis* 2020;20:565-74.
33. Zhang Y, Xiao M, Zhang S, Xia P, Cao W, Jiang W et al. Coagulopathy and Antiphospholipid Antibodies in Patients with Covid-19. *N Engl J Med* 2020.
34. Wu F, Wang A, Liu M, Wang Q, Chen J, Xia S et al. Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications. 2020:2020.03.30.20047365.
35. Whitman JD, Hiatt J, Mowery CT, Shy BR, Yu R, Yamamoto TN et al. Test performance evaluation of SARS-CoV-2 serological assays. 2020:2020.04.25.20074856.
36. Wang X, Guo X, Xin Q, Pan Y, Li J, Chu Y et al. Neutralizing Antibodies Responses to SARS-CoV-2 in COVID-19 Inpatients and Convalescent Patients. 2020:2020.04.15.20065623.

Journal Pre-proof

Table 1: Characteristics of cases reported for new-onset dermatologic conditions in the setting of COVID-19.

	COVID-19 Laboratory Confirmed [†] N(%) (n=171)	COVID-19 Clinically Suspected N(%) (n=511)	Total N (%) (n=682)
Reporter Title			
Dermatologist	81 (47%)	289 (57%)	370 (54%)
Other Physician	63 (37%)	157 (31%)	220 (32%)
Physician Assistant	12 (7.0%)	16 (3.1%)	28 (4.1%)
Nurse Practitioner	5 (2.9%)	17 (3.3%)	22 (3.2%)
Nurse	8 (4.7%)	11 (2.2%)	19 (2.8%)
Other medical professional	2 (1.2%)	21 (4.1%)	23 (3.4%)
Patient Age (Median, IQR)	44 (28-61)	28 (18-42)	30 (19-49)
Patient Sex (Female)	93 (54%)	260 (51%)	353 (52%)
Patient Race/Ethnicity*			
White	115 (67%)	428 (84%)	543 (80%)
Asian	15 (8.8%)	34 (6.7%)	49 (7.2%)
Black/African American	7 (4.1%)	6 (1.2%)	13 (1.9%)
Hispanic/Latino	24 (14%)	10 (1.2%)	34 (5.0%)
Missing	10 (5.8%)	33 (6.5%)	43 (6.3%)
Patient Geographic Region			
North America			
United States	148 (88%)	458 (90%)	606 (89%)
Canada	2 (1.2%)	17 (3.3%)	19 (2.8%)
Europe	10 (5.9%)	25 (4.9%)	35 (5.1%)
Asia	6 (3.6%)	6 (1.2%)	12 (1.8%)
Latin America and the Caribbean	2 (1.2%)	4 (0.8%)	6 (1.8%)
Africa	1 (0.6%)	-	1 (0.1%)
Oceania	-	1 (0.2%)	1 (0.1%)
Condition type			
Skin	166 (97%)	509 (100%)	675 (99%)
Edema	13 (7.6%)	50 (9.8%)	63 (9.2%)
Mucous membrane	8 (4.7%)	10 (2.0%)	18 (2.6%)
Hair	2 (1.2%)	3 (0.6%)	5 (0.7%)
Nail	1 (0.6%)	4 (0.8%)	5 (0.7%)
Morphology of skin change			
Pernio	31 (18%)	391 (77%)	422 (62%)
Morbilliform	38 (22%)	25 (4.9%)	63 (9.2%)
Urticarial	27 (16%)	28 (5.5%)	55 (8.1%)
Macular erythema	23 (14%)	29 (5.7%)	52 (7.6%)
Vesicular	18 (11%)	31 (6.1%)	49 (7.2%)
Acrocyanosis	7 (4.1%)	41 (8.0%)	48 (7.0%)
Acral desquamation	7 (4.1%)	29 (5.7%)	36 (5.3%)
Papulosquamous	17 (9.9%)	15 (2.9%)	32 (4.7%)
Livedo reticularis-like	9 (5.3%)	15 (2.9%)	24 (3.5%)
Erythroderma	4 (2.3%)	17 (3.3%)	21 (3.1%)
Grovers-like	9 (5.3%)	10 (2.0%)	19 (2.8%)
Retiform purpura	11 (6.4%)	7 (1.4%)	18 (2.6%)
Petechial	5 (2.9%)	11 (2.2%)	16 (2.3%)
Bullous	3 (1.8%)	11 (2.2%)	14 (2.1%)
Palpable purpura / vasculitis	5 (2.9%)	7 (1.4%)	12 (1.8%)
Dengue-like	6 (3.5%)	5 (1.0%)	11 (1.6%)
Pressure Injury	8 (4.7%)	2 (0.4%)	10 (1.5%)
Pustular	-	5 (1.0%)	5 (0.7%)
Erythema nodosum	2 (1.2%)	3 (0.6%)	5 (0.7%)
Livedo racemosa	4 (2.3%)	-	4 (0.6%)
Miliaria rubra	2 (1.2%)	1 (0.2%)	3 (0.4%)
Multi-system inflammatory syndrome (MIS-C)	1 (0.6%)	1 (0.2%)	2 (0.3%)
Acneiform	1 (0.6%)	0	1 (0.1%)

* Question not asked of all participants

[†] Confirmed by PCR test, antibody test or unspecified laboratory assay

Table 2: Dermatologic findings in patients with laboratory-confirmed COVID-19.

Laboratory Confirmed COVID-19							
Characteristic	Morbilliform N(%) (n=38) [†]	Pernio N(%) (n=31)	Urticarial N(%) (n=27)	Macular erythema N(%) (n=23)	Vesicular (n=18)	Papulo- squamous N(%) (n=17)	Retiform purpura N(%) (n=11)
Age, years (Median IQR)	52 (36-66)	35 (22-59)	42 (29-54)	31 (27-55)	55 (36-58)	28 (27-38)	66 (51-73)
Female sex*	19 (50.0%)	16 (51.6%)	21 (77.8%)	16 (69.6%)	10 (55.6%)	7 (41.2%)	2 (18.2%)
Body Site Affected							
Face	8 (21%)	-	8 (30%)	6 (26%)	6 (33%)	4 (24%)	-
Head (excluding face)	2 (5.3%)	-	4 (15%)	1 (4.3%)	1 (5.6%)	-	-
Neck	10 (26%)	-	5 (19%)	6 (26%)	1 (5.6%)	4 (24%)	-
Chest	19 (50%)	-	8 (30%)	8 (35%)	6 (33%)	8 (47%)	-
Abdomen	24 (63%)	-	11 (41%)	9 (39%)	8 (44%)	11 (65%)	-
Back	23 (61%)	-	11 (41%)	11 (48%)	6 (33%)	11 (65%)	-
Arm	21 (55%)	-	13 (48%)	11 (48%)	8 (44%)	11 (65%)	2 (18%)
Hand	7 (18%)	10 (32%)	7 (48%)	4 (18%)	7 (39%)	3 (18%)	3 (27%)
Genitals	2 (5.3%)	-	1 (3.7%)	-	2 (11%)	2 (12%)	-
Leg/Buttocks***	22 (58%)	-	14 (52%)	10 (44%)	8 (44%)	11 (65%)	7 (64%)
Foot	7 (18%)	26 (84%)	6 (22%)	5 (22%)	3 (17%)	2 (12%)	2 (18%)
Entire body	4 (11%)	-	4 (15%)	1 (4.3%)	-	-	-
Dermatologic Symptoms							
Asymptomatic	8 (21%)	3 (9.7%)	1 (3.7%)	4 (17%)	2 (11%)	-	8 (73%)
Pain/Burning	6 (16%)	22 (71%)	6 (22%)	6 (26%)	9 (50%)	5 (29%)	1 (9.1%)
Pruritus	23 (61%)	11 (36%)	20 (74%)	14 (61%)	13 (72%)	16 (94%)	-
Timing of dermatologic changes							
Before COVID-19 symptoms	3 (7.9%)	5 (16%)	2 (7.4%)	2 (8.7%)	1 (5.6%)	3 (17.6%)	1 (9.1%)
After COVID-19 symptoms	29 (76%)	15 (48%)	18 (67%)	13 (57%)	13 (72%)	9 (53%)	10 (91%)
At the same time as COVID-19	5 (13%)	3 (9.7%)	6 (22%)	7 (30%)	4 (22%)	4 (24%)	-
No other COVID-19 symptoms	1 (2.6%)	6 (19%)	1 (3.7%)	1 (4.3%)	-	1 (5.9%)	-
Most Likely Etiology, as determined by healthcare provider**							
COVID-19 related	27 (71%)	28 (90%)	20 (74%)	21 (91%)	16 (89%)	13 (77%)	9 (82%)
Related to another virus	4 (11%)	2 (6.5%)	4 (15%)	-	-	2 (12%)	-
Post-viral rash	6 (16%)	-	3 (11%)	1 (4.3%)	2 (11%)	2 (12%)	-
Unsure	1 (2.6%)	1 (3.2%)	-	1 (4.3%)	-	-	2 (18%)
Co-morbid dermatologic condition							
Contact dermatitis	1 (2.6%)	-	-	1 (4.3%)	-	3 (18%)	-
Alopecia areata	-	-	1 (3.7%)	1 (4.3%)	-	2 (12%)	-
Melanoma	2 (5.3%)	1 (3.2%)	-	-	-	-	-
Hidradenitis suppurativa	-	1 (3.2%)	-	-	1 (5.6%)	-	-

*Defined as sex assigned at birth

**Cases determined to be due to a drug have been excluded from this table, and are included in the Supplement

***Leg and buttocks were combined due to questionnaire design, which changed slightly over the course of the study

[†] Because providers could select more than one rash morphology, some patients are double counted (i.e. Patient had both morbilliform rash and pernio)

Table 3: COVID-19 related characteristics of patients with laboratory-confirmed COVID-19 and new onset dermatologic conditions.

Characteristic	Laboratory Confirmed COVID-19						
	Morbilliform N(%) (n=38) [†]	Pernio N(%) (n=31)	Urticarial N(%) (n=27)	Macular erythema N(%) (n=23)	Vesicular (n=18)	Papulo- squamous N(%) (n=17)	Retiform purpura N(%) (n=11)
COVID-19 Diagnosis							
PCR	32 (84%)	16 (52%)	23 (85%)	19 (83%)	16 (89%)	14 (82%)	10 (91%)
Antibody	-	11 (35%)*	-	2 (8.7%)	1 (5.5%)	3 (18%)	-
Unspecified laboratory assay	6 (16%)	4 (13%)	4 (15%)	2 (8.7%)	1 (5.5%)	-	1 (9%)
COVID-19 Exposure							
None	9 (24%)	11 (36%)	9 (33%)	7 (30%)	4 (22%)	6 (35%)	6 (55%)
Unknown	13 (34%)	7 (23%)	6 (22%)	5 (22%)	5 (28%)	4 (24%)	3 (27%)
Close contact with a laboratory confirmed case of COVID-19 infection	9 (24%)	5 (16%)	7 (26%)	7 (30%)	3 (17%)	4 (24%)	1 (9.1%)
Close contact with a probable case of COVID-19 infection	5 (13%)	7 (23%)	4 (15%)	3 (13%)	3 (17%)	3 (18%)	-
Presence in a healthcare facility where COVID-19 infections have been managed	8 (21%)	1 (3.2%)	5 (19%)	2 (8.7%)	3 (17%)	1 (5.9%)	1 (9.1%)
COVID-19 Symptoms							
Fever	28 (74%)	11 (35%)	19 (70%)	15 (65%)	13 (72%)	10 (59%)	7 (64%)
Cough	25 (66%)	11 (35%)	16 (59%)	12 (52%)	11 (61%)	9 (53%)	8 (73%)
Shortness of breath	17 (45%)	9 (29%)	11 (41%)	9 (39%)	5 (28%)	5 (29%)	8 (73%)
Sore throat	15 (40%)	8 (26%)	11 (41%)	9 (39%)	9 (50%)	7 (41%)	3 (27%)
Headache	14 (37%)	7 (23%)	13 (48%)	7 (30%)	6 (33%)	7 (41%)	-
Diarrhea, vomiting or nausea	15 (40%)	7 (23%)	10 (37%)	9 (39%)	5 (28%)	5 (29%)	-
Malaise	12 (32%)	5 (16%)	8 (30%)	9 (39%)	6 (33%)	2 (12%)	3 (27%)
Myalgia	8 (21%)	10 (32%)	9 (33%)	2 (8.7%)	4 (22%)	2 (12%)	-
Irritability/confusion	5 (13%)	3 (9.7%)	5 (19%)	4 (17%)	6 (33%)	4 (24%)	-
Chest pain	2 (5.3%)	2 (6.5%)	7 (26%)	5 (22%)	4 (22%)	5 (29%)	-
Abdominal pain	1 (2.6%)	1 (3.2%)	7 (26%)	5 (22%)	5 (28%)	4 (24%)	-
Anosmia	3 (7.9%)	3 (9.7%)	2 (7.4%)	3 (13%)	5 (28%)	2 (12%)	-
Dysgeusia	1 (2.6%)	2 (6.5%)	5 (19%)	-	2 (11%)	2 (12%)	-
Arthralgia	7 (18%)	1 (3.2%)	3 (11%)	1 (4.3%)	3 (17%)	-	1 (9.1%)
Rhinorrhea	3 (7.9%)	5 (16%)	4 (15%)	1 (4.3%)	1 (5.6%)	-	-
Asymptomatic	1 (2.6%)	6 (19%)	2 (7.4%)	-	-	2 (12%)	-
COVID-19 Testing Criteria*							
Does not meet CDC testing criteria	2 (5.3%)	9 (29%)	2 (7.4%)	1 (4.3%)	-	2 (11.8%)	-
1-2 CDC testing criteria	15 (40%)	13 (42%)	6 (22%)	5 (22%)	7 (39%)	8 (47%)	6 (55%)
3 or more CDC testing criteria	21 (55%)	9 (29%)	19 (70%)	17 (74%)	11 (61%)	7 (41%)	5 (46%)
COVID-19 Treatment							
Supportive care only	19 (50%)	21 (68%)	16 (59%)	14 (61%)	11 (61%)	15 (88%)	-
Anti-malarials	13 (34%)	3 (9.7%)	6 (22%)	4 (17%)	4 (22%)	1 (5.9%)	10 (91%)
Antibiotics	11 (29%)	4 (13%)	6 (22%)	6 (26%)	4 (22%)	-	9 (82%)
Bevacizumab	5 (13%)	-	4 (15%)	1 (4.3%)	2 (11%)	-	-
Remdesivir	2 (5.3%)	1 (3.2%)	2 (7.4%)	1 (4.3%)	1 (5.6%)	1 (5.9%)	1 (9.1%)
Serpin inhibitors	1 (2.6%)	1 (3.2%)	1 (3.7%)	-	1 (5.6%)	2 (11.8%)	-
IL-6 inhibitors	-	-	1 (3.7%)	-	1 (5.6%)	-	2 (18%)
Lipinavir/ritonavir	1 (2.6%)	-	1 (3.7%)	-	-	-	-
JAK inhibitors	-	2 (6.5%)	-	-	-	-	-
COVID-19 Level of Care							
Out-patient care only	21 (55%)	26 (84%)	18 (67%)	14 (61%)	14 (78%)	16 (94%)	0
Hospitalized	5 (13%)	2 (6.5%)	5 (19%)	1 (4.3%)	3 (17%)	1 (5.9%)	0
No supplemental oxygen	6 (16%)	-	2 (7.4%)	4 (17%)	-	-	1 (9.1%)
Supplemental oxygen only	-	1 (3.2%)	0	-	-	-	0
Non-invasive ventilation or high flow oxygen	-	-	-	-	-	-	-
Ventilator and/or ECMO required	6 (16%)	1 (3.2%)	2 (17.4%)	4 (17%)	1 (5.6%)	-	10 (91%)
COVID-19 Complications							

None	27 (71%)	26 (84%)	24 (89%)	17 (74%)	17 (94%)	17 (100%)	-
ARDS	4 (11%)	1 (3.2%)	1 (3.7%)	4 (17%)	1 (5.6%)	-	9 (82%)
Thrombotic event	3 (7.9%)	2 (6.5%)	-	1 (4.3%)	-	-	7 (64%)
Other infection	1 (2.6%)	1 (3.2%)	2 (7.4%)	1 (4.3%)	-	-	6 (55%)
Sepsis	4 (11%)	-	0	2 (8.7%)	-	-	2 (18%)
Acute Kidney Injury	3 (7.9%)	-	-	2 (8.7%)	-	-	2 (18%)
Death	1 (2.6%)	2 (6.5%)	1 (3.7%)	1 (4.4%)	-	-	3 (27%)
Co-Morbid Medical Conditions							
None	21 (55%)	21 (68%)	17 (63%)	13 (57%)	12 (67%)	13 (77%)	2 (18%)
Hypertension	8 (21%)	4 (13%)	3 (11%)	4 (17%)	3 (17%)	3 (18%)	7 (64%)
Diabetes	7 (18%)	-	4 (15%)	1 (4.3%)	2 (11%)	1 (5.9%)	4 (36%)
Obstructive lung disease	3 (7.9%)	-	1 (3.7%)	2 (8.7%)	1 (5.6%)	1 (5.9%)	6 (55%)
Other lung disease	3 (7.9%)	1 (3.2%)	3 (11%)	1 (4.3%)	1 (5.6%)	-	-
Rheumatologic disease	1 (2.6%)	2 (6.5%)	-	-	1 (5.6%)	-	1 (9.1%)
Cardiovascular disease	2 (5.3%)	1 (3.2%)	-	1 (4.3%)	-	-	1 (9.1%)
Kidney disease	1 (2.6%)	-	-	2 (8.7%)	-	2 (12%)	-

*CDC testing criteria reviewed as of May 15, 2020 included fever, cough, sore throat, shortness of breath, myalgia, dysgeusia, anosmia, and vomiting/diarrhea

** 5 IgM positive IgG negative; 1 IgM negative IgG positive; 1 IgM unknown IgG positive; 4 unknown type of antibodies tested

† Because providers could select more than one rash morphology, some patients are double counted (i.e. Patient had both morbilliform rash and pernio)

Table 4: Histologic findings of dermatologic conditions in laboratory confirmed COVID-19 patients.*

Laboratory-confirmed COVID-19			
Clinical lesion morphology	Additional clinical details	Type of COVID-19 testing	Histologic Findings
Thrombotic Vasculopathy			
Retiform purpura	<ul style="list-style-type: none"> • Patient required invasive mechanical ventilation. His course was complicated by ARDS, pulmonary embolism, and retiform purpura on the hands, legs, and feet. 	PCR positive	Thrombotic vasculopathy
Retiform purpura and livedo reticularis	<ul style="list-style-type: none"> • Patient required invasive mechanical ventilation. His course was complicated by ARDS, pulmonary embolism, as well as retiform purpura and livedo reticularis of the arm. 	PCR positive	Thrombotic vasculopathy
Retiform purpura	<ul style="list-style-type: none"> • Hospitalized and required invasive mechanical ventilation. Course was complicated by ARDS, DVT, and retiform purpura of the buttocks. 	PCR positive	Pauci-inflammatory thrombotic vasculopathy
Livedo reticularis	<ul style="list-style-type: none"> • Patient hospitalized and required invasive mechanical ventilation. Eight days later she developed livedo reticularis. 	PCR positive	Pauci-inflammatory thrombotic vasculopathy
Livedo racemosa	<ul style="list-style-type: none"> • Patient required invasive mechanical ventilation, and her course was complicated by ARDS, pulmonary embolism, secondary infection, and livedo racemosa of the hand. 	PCR positive	Thrombotic vasculopathy
Livedo racemosa	<ul style="list-style-type: none"> • Patient required invasive mechanical ventilation. Hospital course was complicated by ARDS, pulmonary embolism, secondary infection, and asymptomatic livedo racemosa of the arm 	PCR positive	Pauci-inflammatory thrombotic vasculopathy
Morbilloform rash, macular erythema, and pressure injury	<ul style="list-style-type: none"> • At the same time as COVID-19 symptoms, patient developed morbilliform rash and macular erythema over the trunk. The patient required invasive mechanical ventilation and developed what appeared to be pressure injury on buttocks 	PCR positive	Biopsy #1 (abdomen): interface dermatitis, ddx includes a drug eruption and viral exanthem. Biopsy #2 (buttock): thrombotic vasculopathy
Skin Necrosis			
Retiform purpura and pressure injury	<ul style="list-style-type: none"> • Patient required invasive mechanical ventilation. Hospital course was complicated by ARDS, secondary infection, and then retiform purpura plus pressure injury on the buttocks. 	PCR positive	Clotting and pressure induced necrosis
LCV			
Palpable purpura and acral desquamation	<ul style="list-style-type: none"> • Patient developed red itchy rash after COVID-19 symptoms, which worsened with erosions and painful ulceration 	IgM positive	LCV
Spongiosis			
Papulosquamous	<ul style="list-style-type: none"> • Developed unilateral rash on anterior shin. Patient was not hospitalized and required no treatment. 	PCR positive	Spongiosis with hyperkeratosis, edema, perivascular lymphocytes, neutrophils, extravasated erythrocytes
Papulosquamous	<ul style="list-style-type: none"> • Presented to dermatology 30 days after onset of COVID-19 symptoms with a papulosquamous eruption. 	PCR positive	Favor pityriasis rosea, histological ddx includes viral exanthem, contact dermatitis or eczema
Other			
Pernio-like	<ul style="list-style-type: none"> • Presented with painful pernio-like lesions of the fingers and toes. 	PCR positive	Mild vacuolar Interface dermatitis, subepidermal edema, and superficial/deep lymphocytic inflammation. Ddx: pernio, autoimmune CTD such as dermatomyositis and SLE
Morbilloform, urticarial and petechial	<ul style="list-style-type: none"> • Patient was hospitalized, intubated, and developed acral distributed petechial, macular and urticarial rash 3-4 weeks following COVID-19 symptoms. • 	PCR positive	Diffuse vacuolar interface dermatitis with numerous dyskeratotic keratinocytes predominantly localized to the basal layer, with lymphocyte exocytosis and sparse superficial perivascular lympho-histiocytic inflammation with rare eosinophils.


Pernio and Grover's-like	<ul style="list-style-type: none"> Two weeks after COVID-19 symptoms patient developed Grover-like rash and pernio 	IgM positive; PCR negative	Granulomatous Dermatitis (colloidal iron demonstrated increased mucin deposition within the center of the granuloma)
--------------------------	---	----------------------------	--

Leukocytoclastic vasculitis: LCV, Abbreviations: Acute Respiratory Distress Syndrome: ARDS, deep vein thrombosis: DVT

* The cases have been grouped in the table by predominant histologic finding.

Figure 1: The spectrum of COVID-19 dermatologic manifestations in all patients, with severity of disease calculated based on percentage of patients with each condition that were hospitalized.

Journal Pre-proof



*Severity calculated based on percentage of patients hospitalized for COVID-19